Histogen (NASDAQ:HSTO) & Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Critical Survey

Profitability

This table compares Calliditas Therapeutics AB (publ) and Histogen’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Calliditas Therapeutics AB (publ)	-30.18%	-212.04%	-27.96%
Histogen	N/A	N/A	N/A

Volatility & Risk

Calliditas Therapeutics AB (publ) has a beta of 1.77, meaning that its stock price is 77% more volatile than the S&P 500. Comparatively, Histogen has a beta of 1.19, meaning that its stock price is 19% more volatile than the S&P 500.

Insider and Institutional Ownership

2.8% of Calliditas Therapeutics AB (publ) shares are owned by institutional investors. 2.2% of Calliditas Therapeutics AB (publ) shares are owned by company insiders. Comparatively, 3.3% of Histogen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares Calliditas Therapeutics AB (publ) and Histogen”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Calliditas Therapeutics AB (publ)	$1.60 billion	0.74	-$43.96 million	($1.85)	-21.62
Histogen	$19,000.00	0.28	-$10.62 million	($2.81)	0.00

Histogen has lower revenue, but higher earnings than Calliditas Therapeutics AB (publ). Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than Histogen, indicating that it is currently the more affordable of the two stocks.

Summary

Histogen beats Calliditas Therapeutics AB (publ) on 6 of the 11 factors compared between the two stocks.

About Calliditas Therapeutics AB (publ)

Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia. It offers Nefecon (TARPEYO/Kinpeygo), an oral formulation of budesonide to reduce the loss of kidney function in adults with immunoglobulin A nephropathy. The company's lead compound is Setanaxib, a NOX inhibitor that is in Phase 2b clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for solid tumors and Alport Syndrome. Calliditas Therapeutics AB (publ) was incorporated in 2004 and is headquartered in Stockholm, Sweden.

About Histogen

Histogen Inc., a clinical-stage therapeutics company, focuses on developing clinical and preclinical small molecule pan-caspase and caspase selective inhibitors that protect the body’s natural process to restore immune function. The company’s product candidates include emricasan for the treatment of acute bacterial skin and skin structure infections, as well as other infectious diseases. Its preclinical product candidates include CTS-2090 and CTS-2096, which are selective small molecule inhibitors of caspase-1 designed for the treatment of various inflammatory diseases. Histogen Inc. was founded in 2007 and is based in San Diego, California. On April 18, 2024, Histogen Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of California.